Birtan Yoldaş Doğan
Research Subjects
Research Interests
Birtan Yoldaş Doğan has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Hamit Yasar Ellidag
Department of Biochemistry, University of Health Sciences, Antalya Training and Research Hospital, Antalya, Turkey
1 shared publication - Mehmet Nuri Koşar
Department of General Surgery, Antalya Training and Research Hospital, Antalya, Turkey
1 shared publication - Uğur Doğan
University of Health Sciences Antalya Training and Research Hospital
1 shared publication
Latest Publications
- 17 March 2026
- Published by Cukurova Anestezi ve Cerrahi Bilimler Dergisi in Cukurova Anestezi ve Cerrahi Bilimler Dergisi
- Vol. 9 (1) , 6-11
Evaluation of Orexin A and Orexin B Levels after Bariatric Surgery in Patient with Obesity
This study aimed to evaluate the changes in serum Orexin A and B levels following laparoscopic sleeve gastrectomy (LSG) in patients with obesity. Methods: Thirty obese patients undergoing LSG were evaluated at baseline, 3 months, and 6 months postoperatively for Orexin A and B levels and BMI. Results: A significant reduction in BMI was observed at postoperative 3 and 6 months (p < 0.001). Orexin B levels significantly declined at 6 months compared to preoperative and 3-month values (p = 0.002), while changes in Orexin A were not statistically significant. No correlation was found between orexin levels and BMI. Conclusions: Postoperative reductions in Orexin B may reflect a role in appetite regulation following bariatric surgery. These findings support further investigation into orexin-targeted therapies in obesity management. Methods: Preoperative, postoperative 3rd, and 6th-month venous blood samples were collected from 30 obese patients diagnosed with obesity and undergoing LSG to measure Orexin A and B levels. The obtained values and body maSD indexes (BMI) calculated at the same time intervals were compared. This study was approved by the Clinical Research Ethics Committee of the University of Health Sciences Antalya Training and Research Hospital (Approval Date: August 5, 2021; Approval No: 11/10) and was conducted in accordance with the Declaration of Helsinki. Conclusions: Previous experimental studies have shown that Orexin peptides are activated in the fasting state and play an active role in obesity by increasing food intake. In this study, we found that Orexin B levels were significantly reduced in patients who experienced weight loss. We believe that monitoring Orexin levels can be beneficial in the treatment of obesity, and inhibiting its activity at the hypothalamic level can contribute to the treatment by reducing food intake. Conducting new studies with a larger number of patients and longer follow-up periods will lead to radical and effective changes in the treatment of obesity.
- 17 March 2026
- Published by Cukurova Anestezi ve Cerrahi Bilimler Dergisi in Cukurova Anestezi ve Cerrahi Bilimler Dergisi
- Vol. 9 (1) , 6-11
Evaluation of Orexin A and Orexin B Levels after Bariatric Surgery in Patient with Obesity
This study aimed to evaluate the changes in serum Orexin A and B levels following laparoscopic sleeve gastrectomy (LSG) in patients with obesity. Methods: Thirty obese patients undergoing LSG were evaluated at baseline, 3 months, and 6 months postoperatively for Orexin A and B levels and BMI. Results: A significant reduction in BMI was observed at postoperative 3 and 6 months (p < 0.001). Orexin B levels significantly declined at 6 months compared to preoperative and 3-month values (p = 0.002), while changes in Orexin A were not statistically significant. No correlation was found between orexin levels and BMI. Conclusions: Postoperative reductions in Orexin B may reflect a role in appetite regulation following bariatric surgery. These findings support further investigation into orexin-targeted therapies in obesity management. Methods: Preoperative, postoperative 3rd, and 6th-month venous blood samples were collected from 30 obese patients diagnosed with obesity and undergoing LSG to measure Orexin A and B levels. The obtained values and body maSD indexes (BMI) calculated at the same time intervals were compared. This study was approved by the Clinical Research Ethics Committee of the University of Health Sciences Antalya Training and Research Hospital (Approval Date: August 5, 2021; Approval No: 11/10) and was conducted in accordance with the Declaration of Helsinki. Conclusions: Previous experimental studies have shown that Orexin peptides are activated in the fasting state and play an active role in obesity by increasing food intake. In this study, we found that Orexin B levels were significantly reduced in patients who experienced weight loss. We believe that monitoring Orexin levels can be beneficial in the treatment of obesity, and inhibiting its activity at the hypothalamic level can contribute to the treatment by reducing food intake. Conducting new studies with a larger number of patients and longer follow-up periods will lead to radical and effective changes in the treatment of obesity.